PremiumThe FlyTyra Biosciences management to meet with Oppenheimer Tyra Biosciences assumed with an Overweight at Piper Sandler Tyra Biosciences Reports Increased R&D Investment in Q1 2025 PremiumRatingsMitchell Kapoor Issues Buy Rating for Tyra Bioscience Due to TYRA-300’s Potential in NMIBC and ACH Markets Tyra Biosciences Advances Precision Medicine Pipeline Tyra Biosciences price target lowered to $28 from $29 at BofA PremiumThe FlyTyra Biosciences initiated with a Buy at UBS Tyra Biosciences price target lowered to $29 from $31 at BofA Tyra Biosciences price target lowered to $30 from $32 at H.C. Wainwright 
